Clinical Trial: Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

U.S., July 19 -- ClinicalTrials.gov registry received information related to the study (NCT07071961) titled 'Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]' on July 16.

Brief Summary: To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy

Study Start Date: Jan. 01, 2026

Study Type: INTERVENTIONAL

Condition: Colorectal Cancer Regorafenib High Risk Patients

Intervention: DRUG: Regorafenib (...